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Pe´ter Bay,1,3,4 Viktor Dombra´di,1 and Bea´ta Lontay1
Free fatty acid receptor 2 (FFAR2, also known as GPR43) is a G-protein-coupled receptor activated by short-chain
fatty acids that are produced by gut microbiota through fermentation of nondigestible carbohydrates. FFAR2
functions as ametabolic sensor and is expressed inmetabolically active tissues, such as adipose tissue. Earlier studies
proved the connection betweenFFAR2and adipocyte differentiation inmice. The aimof this studywas to investigate
the implication of FFAR2 receptor in adipogenesis in human chorion-derivedmesenchymal stemcells (cMSCs). The
short-chain fatty acid, propionate, and phenylacetamide a selective FFAR2 agonist resulted in a marked suppression
of lipid droplet accumulation during the adipogenic differentiation of cMSCs. Western blot studies revealed that
FFAR2 was detectable at any time point of the differentiation period. The direct involvement of FFAR2 in the
differentiation into adipocytes was proven by the downregulation of its gene expression in cMSCs by lentiviral
messenger RNA (mRNA) silencing transduction particles. Our results showed that a significant suppression in lipid
accumulation upon FFAR2 agonist treatments was elicited by FFAR2-silencing. Based on these results we suggest
that propionate inhibits the formation of adipocytes fromMSCs and acts on adipogenesis predominantly via FFAR2.
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Introduction
The fundamental role of adipocytes is to store energyin the form of triacylglycerol when the energy intake is
higher than the expenditure and to mobilize the stored lipid
content when energy is required [1–3]. Overweight and
obesity, an excessive fat accumulation, are the results of the
long-term increased intake of energy-rich foods and the lack
of physical activity that is the characteristic of modern life-
style [4,5]. According to the World Health Organization, the
worldwide prevalence of obesity more than doubled in the
last 30 years including childhood obesity, therefore to face
one of the most serious public health challenges it is neces-
sary to understand the mechanism and regulation of adipo-
genesis (www.who.int/mediacentre/factsheets/fs311/en).
Mesenchymal stem cells (MSCs) are defined as cells capa-
ble of expansion, self-renewal, and differentiation into osteo-
cytic, chondrocytic, and adipocytic lineages when stimulated
under specific conditions [2,6–8]. They can be found in many
fetal and adult tissues, including adipose tissue [9,10], bone
marrow [11,12], and umbilical cord [8,13]. However, their use
for research purposes is restricted either by the invasive pro-
cedures by which they are obtained or by their low yields and
limited proliferative capacity. On the other hand, human pla-
centa is a rich source of multipotent stem cells, it can be easily
obtained at the end of gestation when the placenta is delivered
and usually discarded, and its use is not restricted by ethical
issues [6–8]. MSCs are considered as an alternative source for
cell therapy and regenerative medicine, and they can also serve
as a good model for adipogenesis [14].
Recent investigations have demonstrated that the gut mi-
crobiota is involved in obesity through producing short chain
fatty acids (SCFAs) such as acetate, propionate, and butyrate,
the fermentation products of dietary fibers [4,15]. SCFAs not
only serve as energy sources for the host but also act as sig-
nalingmolecules throughG-protein-coupled receptors exerting
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multiple effects on metabolic regulation [5]. In the family of
the free fatty acid binding receptors (FFARs), two receptors—
FFAR2 and FFAR3, also known as G-protein-coupled receptor
43 (GPR43) and G-protein-coupled receptor 41 (GPR41)—
have been recently described to be activated by SCFAs [4,16].
Acetate and propionate are the most potent agonists of FFAR2,
whereas propionate proved to be the most active agent af-
fecting FFAR3 [17,18].
Both receptors exhibit similar tissue localization [19–25],
however, FFAR3 is exclusively expressed in some regions
of the sympathetic nervous system [26,27] and only FFAR2,
but not FFAR3, is expressed in adipocytes [15,28,29].
Contrary to the previous findings it has been recently re-
ported that in white adipose tissue of mice FFAR2 activation
by SCFAs suppresses adipose-insulin signaling, which in-
hibits fat accumulation and promotes the metabolism of
lipids and glucose in other tissues [29].
Although the implication of FFAR2 receptor in adipogen-
esis has been established inmice, its physiological significance
remained uncovered in humans. In this study we use human
chorion-derived mesenchymal stem cells (cMSCs) as an ex-
perimental model and demonstrate that FFAR2 activation by
its endogenous ligand propionate and by a synthetic phenyla-
cetamide ligand FFAR2 agonist decreases the capability of
cMSCs to differentiate into adipocyte lineage and conse-
quently inhibits fat accumulation.
Materials and Methods
Chemicals and antibodies
All chemicals were obtained from Sigma-Aldrich (Saint
Louis,MO) unless otherwise indicated. Antibodies used in this
study are listed in the Supplementary Table S1 (Supplemen-
tary Data are available online at www.liebertpub.com/scd).
Ethic statement
Placentas were obtained at the end of gestation from
healthy human donors. All procedures were authorized by the
Regional and Institutional Ethics Committee of the Uni-
versity of Debrecen, and it was in accordance with the
guidelines of the European Union Council and the Hungarian
regulations under license number DEOEC-RKEB-2946-2009.
Isolation and characterization of cMSCs
cMSCs were isolated from four different healthy donors as
described previously [30,31]. Cell surface markers were de-
termined with flow cytometric analysis (Becton Dickinson BD
FACSCalibur and BDMultiset Software v3.0x for Mac OS X,
Heidelberg, Germany) by using the appropriate antibodies
(Supplementary Table S1) as follows. Cells were considered as
MSCs and used for further analysis if they exhibited the cell
surface markers CD105, CD73, and CD90 but not CD34,
CD45, von Willebrand factor (vWF), and human leukocyte
antigen G (HLA-G), and were able to differentiate down the
adipogenic, osteogenic, and chondrogenic lineages.
Culturing and differentiation of cMSCs and human
adipose-derived MSCs
Human adipose-derived mesenchymal stem cells
(hAMSCs) were cultured in low glucose Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 1% penicillin-
streptomycin solution and 2mM l-glutamine in humidified
atmosphere of 5% CO2 at 37C. Two days after reaching
confluence (day 0), the culturing medium was replaced with
differentiation-inducing medium containing high glucose
DMEM with 10% FBS, 1% penicillin-streptomycin solu-
tion, 2mM l-glutamine, 20mM HEPES (pH 7.4), and in-
ducers such as 1 mM dexamethasone, 200mM indomethacin,
and 0.5mM 3-isobutyl-1-methylxanthine (IBMX) dissolved
in dimethyl sulfoxide (DMSO) and 10 mM insulin (Humulin
R; Eli Lilly). cMSCs were seeded in 96-well microplates
and differentiation was induced with a differentiation-
inducing medium alone or supplemented with acetate, pro-
pionate or a synthetic phenylacetamide FFAR2 agonist
(Calbiochem, San Diego, CA) dissolved in DMSO in con-
centrations between 3.3 · 10-5–3.3 · 10-3 M for acetate and
propionate and 10-7–1.1· 10-5 M for FFAR2 agonist. Cells
were maintained in this medium up to 14 days and the
medium was changed at days 0, 3, 7, 10, and 14 of differ-
entiation. After the establishment of optimal conditions
3.3mM propionate and 3.7 mM FFAR2 agonist were used in
the subsequent experiments and samples were analyzed on
days 0, 3, 7, 10, and 14 of differentiation.
hAMSCs were isolated from pericardial adipose tissue
and were cultured in DMEM-F12 medium supplemented
with 10% FBS, 1% penicillin-streptomycin solution, and
2mM l-glutamine in humidified atmosphere of 5% CO2 at
37C. Cells were seeded into six-well microplates and dif-
ferentiated according to the protocol described previously
[31]. Medium was changed and samples were analyzed on
days 0, 7, and 14 of differentiation.
Oil Red O staining
Cells were washed in phosphate-buffered saline (PBS)
and then fixed in 4% formaldehyde for 15min at room
temperature. After washing twice in distilled water, cells
were stained in freshly diluted Oil Red O (ORO) solution (in
0.3% final concentration) for 30min at room temperature.
After being washed three times in distilled water, samples
were mounted in Mowiol 4-88 anti-fade solution and visu-
alized by a Leica DM IL LED microscope (Leica, Micro-
systems, Mannheim, Germany).
Nile Red staining
cMSCs were seeded and treated in 96-well microplates.
After removing the supernatants, cells were washed in PBS,
fixed in 4% formaldehyde for 10min at room temperature,
and washed again. Staining was carried out with 10mg/mL
Nile Red solution in dark for 30min at room temperature.
After being washed twice in PBS, fluorescence intensity was
measured at 485/538 nm in a microplate fluorimeter
(Fluoroscan Ascent FL; Thermo Fisher Scientific, Waltham,
MA). Data acquisition and processing were done using the
Ascent Software Ver. 2.6. Protein concentrations were de-
termined by BCA protein assay kit (Thermo Scientific,
Schwerte, Germany) at 540 nm in an enzyme-linked im-
munosorbent assay (ELISA) Reader (Labsystem Multiscan
MS, Mountain View, CA). The fluorescence intensity was
normalized to the protein concentration of each sample and
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was expressed in arbitrary unit/mg protein. To visualize the
Nile Red staining, cells were cultured and treated in 24-well
plates, stained as described above and were analyzed with a
Leica SP8 confocal microscope (Leica, Microsystems).
RNA isolation, reverse transcription, and
quantitative polymerase chain reaction
Total RNA was extracted with TRI Reagent (Molecular
Research Center, Inc., Cincinnati, OH) following the manu-
facturer’s protocol. Isolated RNA were treated with RNase
free DNase (Promega Co., Madison, WI) and reverse tran-
scription (RT) were conducted with qPCRBIO cDNA
Synthesis Kit (PCR Biosystems Ltd., London, UK). Diluted
complementary DNA (cDNA) were amplified in RT-coupled
quantitative polymerase chain reaction (RT-qPCR) with
qPCRBIO SyGreen Lo-ROX Supermix (PCR Biosystems
Ltd.) using Light-Cycler 480 system (Roche Applied Sci-
ence, Penzberg, Germany). The gene expression levels were
normalized to 18S as a reference housekeeping gene prod-
uct. The primer pairs used in the RT-PCR experiments are
listed in Supplementary Table S2.
Cell viability assay
The percentage of viable cells was quantified by MTT
assay. Cells were treated in 96-well microplates as de-
scribed above and on day 14 of differentiation supernatants
were discarded and cells were exposed to 0.5mg/mL MTT
[3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium] solu-
tion. The solution was replaced with DMSO after incubation
for 1 h at 37C, and the absorbance was measured at 570 nm
using a microplate reader (Labsystem Multiscan MS). The
acquisition and processing of the data were performed with
the Ascent Software, version 2.6.
FFAR2 gene silencing in cMSCs
cMSCs were infected by incubation with FFAR2-specific
lentiviral transduction particles (construct TRCN0000357229
of Sigma-Aldrich) at a multiplicity of infection of 5 in the
presence of 8 mg/mL hexadimethrine bromide. Cells trans-
duced with empty TRC pLKO.1 (Einstein shRNA Core
Facility) and TRC2 pLKO.5-puro nontarget small hairpin
RNA (nt shRNA) control transduction particles (Sigma-
Aldrich) were applied in control experiments. The virus-
containing supernatant was removed after 48 h and the
transduced cells were selected in the presence of puromycin
(3 mg/mL) according to the manufacturer’s protocol. The
efficiency of FFAR2 silencing was verified by western blot
analysis.
Western blot analysis
Western blotting was done as described previously [32].
Briefly, cells were lysed in RIPA buffer and 30mg of protein
lysates were analyzed by western blot using primary anti-
bodies and the anti-rabbit IgG peroxidase conjugate or the
anti-mouse IgG HRP-linked secondary antibodies (Supple-
mentary Table S1). The immunoreactive bands were detected
by Super Signal West Pico chemiluminescent substrate
(Thermo Fisher Scientific) and imaged with FluorChem
FC2 Imager (Alpha Innotec, Kasendorf, Germany) and
ChemiDoc Touch Imaging System (BIO-RAD, Hercules,
CA). Densitometry of the proteins of interest was performed
by Image J. 1.46 (NIH, Bethesda, MD). The data were
normalized to an internal control protein, and were plotted
as relative numbers as described in figure legends.
Statistical analysis
Normalized data were analyzed by either unpaired t-test
or one-way analysis of variance (ANOVA) for two groups
or two-way ANOVA for more than two groups. Dunnett’s or
Tukey’s multiple comparison tests were used as post hoc
tests for one-way or two-way ANOVA. Parametric statisti-
cal tests were used if the requirements of such tests were
met. Calculations were conducted with the GraphPad for
Windows software. All normalized variables used in sta-
tistical analyses were found to obey normal distribution.
Data presented in this work represent mean – standard de-
viation, n means the number of independent experiments.
Results
cMSCs differentiate to adipocytes
The minimal criteria to define MSCs are plastic adher-
ence, expression of a specific surface antigen pattern and the
ability to differentiate into osteocytic, chondrocytic, and
adipocytic lineages [10]. The capacity of human cMSC to
differentiate into adipocytes was verified in the presence of a
medium containing the mixture of adipogenic inducers such
as dexamethasone, indomethacin, IBMX, and insulin as
described in the previous section. During the 14-day-long
differentiation period, stem cells lost their fibroblastic
morphology and accumulated triglyceride in their cytoplasm
as shown by ORO (Fig. 1A) and Nile Red stainings
(Fig. 1B) at day 14. Intracellular lipid content was quantified
based on the fluorescence intensity of the Nile Red dye.
Figure 1C demonstrates that significant amount of triglyc-
eride accumulated as early as day 3 of differentiation, which
increased further up to sixfold at the end of the course of
adipogenesis (P < 0.001). Beside triglyceride formation that
is closely related to an increased rate of de novo lipogenesis,
numerous proteins are coordinately expressed during dif-
ferentiation [2]. Two of them, the peroxisome proliferator-
activated receptor-g (PPARg)—the master regulator of the
adipogenesis program—and the ‘‘satiety’’ hormone leptin
made by adipocytes were examined by RT-qPCR. By the
end of differentiation the expression levels of these marker
genes increased up to 3.52-fold and 7.83-fold, respectively
(Supplementary Fig. S1A, B). These results were confirmed
by western blot analysis showing that the amount of leptin
(Fig. 1D) and PPARg (Fig. 3D, left upper panel) proteins
increased throughout the differentiation procedure. Since
most of the previous studies on free fatty acid signaling were
performed in adipose tissue, we also applied hAMSCs for
comparison. Extensive lipid droplet formation at day 14
proved that these cells were also differentiated into adipo-
cytes (Supplementary Fig. S1C).
The expression of FFAR2 receptor in cMSCs
FFAR2 is known to be activated upon binding propionate
that appears to be the most potent agonist for the receptor
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[17]. To reveal the possible target of our treatments, the
FFAR2 protein levels were examined throughout the 14-day
long cMSC differentiation by western blot analysis. The
FFAR2 protein can be detected at any time point of the
differentiation period with somewhat lower level at day 0
(Fig. 1E). Receptor expression was more pronounced from
day 3 without any significant difference throughout the
whole period suggesting that the differentiation itself does
not influence the abundance of FFAR2. In comparison, in
hAMSCs an increased FFAR2 expression was detected by
day 14 relative to the undifferentiated control (Supplemen-
tary Fig. S1D). The expression of FFAR3—the other SCFA-
binding receptor—was also studied in cMSC by RT-qPCR
and in both cMSC and hAMSC by western blot analysis,
too. The FFAR3 expression was below detection level in all
of the investigated MSCs by any of the applied methods
(Supplementary Fig. S1E and western blots not shown)
suggesting that FFAR2 is the major receptor of SCFAs in
these cell lines.
cMSC adipogenic differentiation is suppressed
by propionate and by an FFAR2 agonist
The short-chain fatty acids acetate and propionate—the
endogenous ligands for FFAR2 and FFAR3—have been
reported to stimulate adipogenesis through FFAR2 but not
through FFAR3 in mouse 3T3-L1 cells [33]. To reveal the
role of the FFAR2 receptor in human cMSCs, lipid accu-
mulation was determined at day 14 of differentiation in the
presence of increasing concentrations of acetate, propionate,
or phenylacetamide, a synthetic FFAR2 agonist (Fig. 2). After
14 days of differentiation, there was no significant effect of
acetate on the lipid content of the differentiated cMSCs as
compared to the differentiated untreated group (Fig. 2A). In
contrast, propionate and the FFAR2 agonist significantly re-
duced the fluorescence intensity in a concentration-dependent
manner. The suppression of lipid accumulation in differen-
tiating cMSCs was 31% at 3.3 · 10-3 M propionate and 61%
at 3.7 · 10-6 M FFAR2 agonist (Fig. 2B, C). Interestingly,
the effects of acetate and propionate on adipogenesis were
different and propionate showed a similar effect to the
FIG. 1. Chorion-derived MSCs differentiate to adipo-
cytes. Neutral lipid accumulation was detected by (A) Oil
Red O (red color) or (B) Nile Red (green fluorescence)
staining in cMSCs from four different donors of placenta at
the beginning (D0) and at the end (D14) of the 14-day long
adipogenic differentiation protocol. Representative pictures
of four independent experiments are shown (scale bar = 50
mm). The time course of cMSC differentiation (DIFF) into
adipocytes was followed by measuring the fluorescence in-
tensity of the Nile Red stained cells from four different
donors in five independent experiments (C). Data were
normalized to the protein mass of the samples and are given
in a.u./mg. Normalized intensities were compared to the
nondifferentiated control samples (NDC) by one-way AN-
OVA with Dunnett’s multiple comparison test as a pos hoc
test (n = 4, **P< 0.01, ***P < 0.001). The protein levels of
leptin and FFAR2 were detected at days 0, 3, 7, 10, and 14
of adipogenic differentiation (D0, D3, D7, D10, D14) in
cMSCs from two different donors by western blot analysis
with Ob(leptin) and FFAR2-specific antibodies, respectively
(D, E). GAPDH was used as an internal control. Following
the densitometry of the stained bands FFAR2 data were
normalized to GAPDH, and were plotted as percentage of
the initial (D0) levels (E) (one-way ANOVA with Dunnett’s
and Tukey multiple comparison post hoc tests, n= 2). AN-
OVA, analysis of variance; a.u., arbitrary unit; cMSCs,
chorion-derived mesenchymal stem cells; FFAR, free fatty
acid receptor; MSCs, mesenchymal stem cells. Color images
available online at www.liebertpub.com/scd
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highly specific FFAR2 agonist. To confirm our initial ob-
servations we used 3.3 · 10-3 M propionate and 3.7 · 10-6
M FFAR2 agonist in our next experiments, while the acetate
effect was not pursued further on.
First we tested whether propionate or the FFAR2 agonist
had any effect on the number of viable cMSCs (Fig. 3A).
MTT assays revealed that during differentiation the relative
viability of the cells decreased to 50.25%, 39.53%, and
54.03% without additions and in the presence of propionate
or FFAR2 agonist, respectively, as compared to the non-
differentiated control cell cultures (Fig. 3A). Nevertheless,
there was no significant difference between the differenti-
ated control and FFAR2 agonist treated groups, and only a
slight change was measured in the case of the propionate
treated group (P < 0.05) suggesting that cell loss was a
consequence of the differentiation process rather than the
treatments. All of the differentiated groups differed signifi-
cantly (P < 0.001) from the nondifferentiated controls.
To study the effects of propionate or FFAR2 agonist
treatments on the 2-week long cMSC adipogenesis, lipid
accumulation was visualized by ORO (Fig. 3B) or quantified
by Nile Red (Fig. 3C) stainings on every third day of the 14-
day long procedure. Lipid-producing cells were detected as
early as day 3 of differentiation and a significant reduction
in staining intensity was also observed in both of the treated
groups from day 7 as compared to the differentiated controls.
These effects became more pronounced as the differentiation
proceeded and by days 10 and 14 markedly less lipids ac-
cumulated in the propionate treated (44.47% and 42.19%
decrease, respectively; P< 0,001) or FFAR2 agonist treated
cells (42.99% and 50.16% decrease, respectively; P< 0.001;
Fig. 3C). Overall, these results confirm that propionate and
FFAR2 agonist suppress adipogenesis in cMSCs.
As previously we found that cMSCs express PPARg
(Fig. 3D) and FFAR2 proteins (Figs. 1E and 3D) throughout
adipogenic differentiation we investigated the effect of
propionate and FFAR2 agonist treatment on the expression
of these two markers. Our western blot results showed sig-
nificantly lower levels of PPARg upon both treatments at
days 10 and 14 compared to their nontreated differentiated
counterparts (Fig. 3D) in correlation with the pronounced
reduction in lipid accumulation (Fig. 3B, C). These data
suggest a negative regulatory role of propionate and FFAR2
agonist on adipogenesis. We found no significant changes in
FFAR2 protein level upon propionate treatment while
FFAR2 agonist resulted in a slight decrease of the FFAR2
expression in the second half of the adipogenic differenti-
ation procedure (Fig. 3D).
FFAR2 receptor is the mediator of the
propionate action in cMSC
Since the FFAR2 receptor for propionate was found to be
expressed in cMSCs and it has been demonstrated to be
involved in adipogenesis, we aimed to unravel its role in the
signaling pathway responsible for SCFA action. FFAR2
gene expression was downregulated by lentiviral transduc-
tion particles in cMSCs and the effect of silencing was ex-
amined on the process of adipogenesis. The efficiency of the
shRNA based silencing was demonstrated at day 14 of
differentiation by western blot analysis that revealed a
*92% reduction in the FFAR2 protein level in contrast to
FIG. 2. Effects of SCFAs acetate and propionate and an
FFAR2 agonist on cMSCadipogenesis. Lipid accumulationwas
determined by measuring the fluorescence intensity of the Nile
Red stained cells from three different donors with five parallels
at day 14 of differentiation in the absence (DIFF) or presence of
increasing concentrations of the FFAR2 ligands acetate (A) and
propionate (B) and FFAR2 agonist phenylacetamide (C). Rep-
resentative results of three independent experiments are shown.
Data were normalized to the proteinmass of the samples and the
normalized fluorescence intensities were compared to the dif-
ferentiated controls (DIFF) byone-wayANOVAwithDunnett’s
multiple comparison test as a pos hoc test (n= 3, **P< 0.01,
***P<0.001). SCFAs, short chain fatty acids.
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FIG. 3. Propionate and the FFAR2 agonist phenylacetamide suppress cMSC adipogenic differentiation. Relative cell
viability of nondifferentiated, differentiated (DIFF), and differentiated cMSCs either in the presence of propionate (PROP,
3.3 · 10-3 M) or phenylacetamide (FFAR2 agonist 3.7 · 10-6 M) was determined by MTT assay at the end of the 14 days
differentiation protocol (A). Relative viability assay was performed on cMSCs originated from three donors with five
parallels (one-way ANOVA with Dunnett’s multiple comparison post hoc test, n= 3, *P< 0.05). Neutral lipid accumulation
was detected by Oil Red O staining on differentiating cMSCs from two donors at day 3, 7, 10, and 14 of differentiation
without additions (DIFF), or upon 3.3 · 10-3 M propionate (PROP) and 3.7 · 10-6 M FFAR2 agonist treatment (FFAR2
agonist). Representative pictures of two independent experiments are shown (B). Lipid droplets were measured based on the
fluorescence intensity of the Nile Red stained cells at day 0, 3, 7, 10, and 14 of differentiation (D0, D3, D7, D10, D14) upon
3.3 · 10-3 M propionate (PROP) and 3.7 · 10-6 M FFAR2 agonist treatment (FFAR2 agonist) and were compared to the
differentiated group without any treatment (DIFF). Experiments were done on cMSCs from four donors with eight parallels.
Fluorescence data were normalized to the protein mass of the sample and compared to the differentiated samples (two-way
ANOVA with Dunnett’s multiple comparison post hoc test, n = 4, ***P < 0.001) (C). Western blot analysis of PPARg- and
FFAR2 expression was conducted at days 0, 3, 7, 10, and 14 of adipogenic differentiation in nontreated differentiated
cMSCs (DIFF) or upon 3.3 · 10-3 M propionate (PROP) and 3.7 · 10-6 M FFAR2 agonist treatments (FFAR2 agonist) (D).
Two independent experiments were performed from one donor for PPARg and two different donors were used for FFAR2.
GAPDH was used as an internal control. The results of a representative experiment are shown in the panel. PPARg,
peroxisome proliferator-activated receptor-g. Color images available online at www.liebertpub.com/scd
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the control nt shRNA transduction that had no effect on
FFAR2 (Fig. 4A). To determine whether the reduction of
FFAR2 protein level influences lipid accumulation during
adipogenesis, we examined the lipid contents after propio-
nate or the highly specific FFAR2 agonist treatments. First,
the lipid accumulation of cMSCs transduced with empty
TRC pLKO.1 (no shRNA) and TRC2 pLKO.5-puro non-
target shRNA control transduction particles (nt shRNA) was
determined. We found 39.1% and 21.4% (P< 0.01) decrease
in lipid content at the beginning (day 0) and 31.2% and
32.7% decrease (P < 0.01 and P< 0.001) at the end (day 14)
of differentiation, respectively, relative to the nontreated
controls (Supplementary Fig. S2). Our control experiments
suggest that the lentiviral infection alone had a significant
effect on adipogenic differentiation. However, as there was
no difference between the effects of no shRNA and nt
shRNA transductions on lipid accumulation at any time of
differentiation, we deemed it appropriate to use nt shRNA as
a proper control for the quantitative evaluation of the effect
of FFAR2-silencing on cMSCs. Our results show that
FFAR2 agonist treatment significantly decreased the lipid
accumulation at day 14 of differentiation in the nt shRNA
treated group (22.27% decrease, P < 0.05) compared to their
differentiated counterparts (Fig. 4B). On the other hand,
after FFAR2 silencing upon the same treatment the lipid
droplet formation showed no significant change relative to
the FFAR2 silenced, differentiated group (Fig. 4B). These
data suggest that the FFAR2 receptor exerts inhibitory ef-
fects on adipogenesis and the endogenous or pharmacolog-
ical ligands, propionate and synthetic phenylacetamide
FFAR2 agonist, may reduce triglyceride formation acting
through the FFAR2 receptor Nevertheless, MTT assay re-
vealed that the relative cell viability decreased to 66.9%
(P < 0.001) in the FFAR2 silenced group compared to the
FIG. 4. Effect of FFAR2 silencing on the process of
adipogenesis in cMSCs. (A) cMSCs were transduced with
FFAR2-specific and nontarget control shRNA transduction
particles and the efficiency of the silencing was verified at
day 14 of differentiation by western blot analysis with two
different FFAR2-specific antibodies (Supplementary
Table S1). Two independent experiments were performed
with cMSCs from two donors. The lower panel shows one
representative result obtained with Anti-FFAR2/GPR43
antibody. GAPDH was used as an internal control. Protein
levels of FFAR2 were normalized to the intensity of
GAPDH and were calculated for ctr: not transduced control,
nt shRNA: nontarget shRNA, shFFAR2: shFFAR2-silenced
samples and were analyzed by the Student t-test (n = 4,
***P < 0.001). (B) Lipid accumulation of FFAR2 silenced
(shFFAR2) cMSCs was determined by measuring the fluo-
rescence intensity of the Nile Red stained cells at day 14 of
differentiation (DIFF) upon FFAR2 agonist treatment and
was compared to the nontarget control (nt shRNA). Fluor-
escence data were normalized to the protein mass of the
samples and are given in a.u./mg. Normalized intensities
were analyzed by one-way ANOVA with Tukey’s multiple
comparison post hoc statistical test (n = 2, *P < 0.05,
**P < 0.01, ***P < 0.001, ns). (C) Relative cell viability was
measured by MTT assay at the end of the 14 days differ-
entiation protocol upon FFAR2 agonist treatment in non-
target control and FFAR2 silenced cMSCs originated from
one donor. Two independent experiments were performed
with three parallels (one-way ANOVA with Tukey’s multiple
comparison post hoc test, n= 2, **P< 0.01, ***P< 0.001).
GPR43, G-protein-coupled receptor 43; n.s., not significant
change; shRNA, small hairpin RNA.
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nontarget shRNA treated, nondifferentiated groups sug-
gesting a possible role of FFAR2 receptor in cell survival
(Fig. 4C). Shi et al. described that the overexpression of
FFAR2 in HEK283T cells induced apoptosis through ERK
signaling [22]. Therefore, the presence of the proapoptotic
cleaved poly-(ADP-ribose) polymerase (cPARP) protein
and the activation of ERK signaling were determined in
control, nontarget control, and FFAR2-silenced cMSC at
day 14 of adipogenic differentiation. The absence of cleaved
cPARP excludes the activation of apoptosis in any of the
samples (Supplementary Fig. S3A). Neither the protein ex-
pression level of ERK nor the relative phosphorylation level
of ERK (at Thr202/Tyr204) changed (Supplementary
Fig. S3B) suggesting that FFAR2 silencing does not trigger
ERK-mediated apoptotic signaling in differentiated cMSCs.
The relative viability of all the nondifferentiated groups
significantly deviated from their differentiated FFAR2
agonist-treated (Fig. 4C) counterparts. Taken together, there
were no significant differences in cell viability between the
differentiated and FFAR2 agonist treated groups within any
of the analyzed subgroups (Fig. 4C) indicating that the ef-
fects of silencing cannot be attributed to the changes in cell
survival caused by the lentiviral silencing method.
Discussion
Acetate and propionate were previously shown to stimu-
late fat accumulation in mice 3T3-L1-derived adipocytes
[33]. However, no relationship between FFAR2 and adipo-
cyte differentiation has been found in human adipose tissue-
derived stromal vascular cells [28]. In contrast with these
observations, here we report that propionate and FFAR2
agonist suppress the adipogenesis in human chorion-derived
MSCs through the FFAR2 receptor. To answer the question
whether FFAR2 is involved in human adipogenesis, we used
cMSCs as a model system. These cells exhibit the same
morphological features as adipose-derived MSCs with
similar self-renewal and differentiation capacity and on the
other hand the placenta can be easily obtained at the end of
gestation without any invasive intervention [7,9]. In our
experiments, both the chorion- and adipose-derived MSCs
lost their fibroblastic morphology and accumulated cyto-
plasmic triglyceride during the 14-day long differentiation
proving their capability to differentiate into adipocytes.
PPARg [34] and leptin [35] are established markers for
adipogenic differentiation of hAMSC. The fact that an in-
crease was detected in their expression during the course of
the differentiation of both cMSC and hAMSC justifies the
application of adipogenic differentiated cMSC as a valid
model for the investigation of SCFA signaling.
FFAR2 was reported to be highly expressed in mouse and
human adipose tissues but the levels of FFAR2 messenger
RNA (mRNA) were much lower or undetectable in the
stromal-vascular fraction (SVF), a rich source of MSCs
[28,29,33]. Li et al. found that FFAR2 mRNA was not
detectable in porcine SVF before or during adipocyte dif-
ferentiation [36]. Based on our western blot analysis, the
short-chain fatty acid receptor FFAR2 is expressed in un-
differentiated cMSCs, and its protein level increases and
varies slightly without any significant tendency throughout
the differentiation period while FFAR3 was not detected at
any time point. As Hong et al. [33] previously demonstrated,
FFAR2 is implicated in the process of adipogenesis in mice
and the short-chain fatty acid acetate and propionate stim-
ulate fat accumulation in 3T3-L1-derived adipocytes mainly
through FFAR2. In accordance with this finding, FFAR2-
deficient mice is protected from high-fat diet induced
obesity and showed higher energy expenditure than their
wild-type counterparts [37]. In contrast, Kimura et al.
demonstrated that the FFAR2-deficient mice are obese on
normal diet and short-chain fatty acid-mediated activation of
FFAR2 suppresses insulin signaling in adipocytes, which
inhibits fat accumulation in adipose tissue and promotes the
metabolism of unincorporated lipids and glucose in other
tissues [29]. These discrepancies among the publications
may stem from the differences of diet or from the mice
strains with different age, gender, or genetic background or
may be caused by the different SCFA concentrations used in
the experiments. Acetate and propionate concentrations vary
in wide ranges from 0.1 mM up to millimolar values in these
studies. We found that the effective concentrations of
FFAR2 ligands that result in significant change in lipid ac-
cumulation of cMSCs are in millimolar concentration for
propionate and in micromolar range for the FFAR2 agonist.
Total SCFAs are reported to be 100mM in gut lumen that
decreases to 100 mM in peripheral blood, but plasma levels
of acetate could increase up to millimolar concentrations
after alcohol consumption [5,38]. The propionate levels in
human circulation are reported to be between 5 and 88 mM
[39] and only a few inherited diseases caused by specific
enzyme defect result in the accumulation of higher doses of
propionate [40]. In our study, 3mM acetate failed to affect
the fat content in the differentiated cMSCs while the same
amount of propionate, which is considerably above the
physiological level in the blood, but relevant in the gut lu-
men, significantly decreased it. The same concentration of
butyrate was cytotoxic for the cMSCs (data not shown). The
effects of propionate are similar to the FFAR2 agonist, but
according to our data acetate and propionate—the physio-
logical ligands of FFAR2—act differently. Our results are
not in agreement with published results [33] showing that
acetate and propionate stimulate fat accumulation in 3T3-
L1-derived adipocytes, however, are well in line with a
previous study describing distinct effects on 3T3-L1 adi-
pogenesis [41] that suggests the selective sensitivity of stem
cells toward SCFAs.
The available information on the role of FFAR2 in human
adipogenesis is limited. The data obtained with human ad-
ipose tissue-derived stromal-vascular cells treated with
10mM acetate and propionate suggested the absence of any
relationship between FFAR2 and adipocyte differentiation
[28]. Nevertheless, we demonstrated in human cMSCs that
adipogenic differentiation is suppressed by propionate that
acts as an endogenous ligand for FFAR2 and the synthetic
FFAR2 agonist phenylacetamide had the same effect. The
inhibitory mechanism might be related to an inhibitory G
protein (Gi) linked to FFAR2 and upon agonist activation it
could result in a decrease in the adipogenic differentiation
[29,42]. As the FFAR3 was reported to be expressed neither
in human nor in mice adipose tissues or in SVF cells [33], and
we found neither the mRNA nor the protein of FFAR3 in
cMSC and hAMSC, we assume that these effects were me-
diated exclusively by FFAR2. Indeed, the action of FFAR2
agonist phenylacetamide activating specifically the FFAR2
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receptor was also suppressed by FFAR2 silencing, just as it
was the case for propionate treatment. Taken together our
results confirm the role of FFAR2 in human adipogenesis.
In conclusion, our results revealed the inhibitory role of
FFAR2 in fat accumulation in human cMSCs and its role in
the propionate-induced inhibition of adipogenic differenti-
ation. MSCs have been identified in numerous tissues and
virtually all of the tissues may contain MSCs in various
proportions. The suppression of adipogenesis by the bacte-
rial product short-chain fatty acid propionate could be a
possible mechanism of regulating the energy homeostasis
and inhibiting the undesirable formation of adipocytes
throughout the body. Since FFAR2 is considered to be a key
component of the body’s nutrient sensing mechanism, tar-
geting these receptors may offer novel therapies for the
management of obesity and other metabolic disorders.
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